HUM · Humana Inc.

The annual meeting results reflect broad investor support for Humana’s current governance structure and compensation framework, with all director nominees elected and key management proposals approved. The high level of broker non-votes (5.74 million shares) across four proposals—excluding auditor ratification—suggests institutional investors relied on discretionary voting authority rather than specific instructions, a common pattern for routine governance items. While the advisory vote on executive compensation passed comfortably, the 4.7 million 'Against' votes represent approximately 4.3% of shares voted, slightly above typical dissent thresholds and warranting attention in future proxy disclosures. The rejection of the golden parachute proposal—with 59.1 million 'Against' votes—underscores limited appetite among shareholders for additional constraints on change-in-control arrangements, possibly reflecting confidence in existing board oversight or concerns about competitive talent retention. No director received more than 16.6% 'Against' votes, and the lowest 'For' vote count (85.2 million for Dr. Frederick) still represented over 79% of shares present and voted, confirming no material governance concern emerged from the balloting. The absence of any contested director elections, auditor challenges, or failed management proposals signals stability in corporate leadership and strategic direction.